BS006 / Wuhan Binhui Biotech - LARVOL DELTA

oHSV2-PD-L1/CD3-BsAb Administered Via Intratumoral Injection (clinicaltrials.gov) - P1 | N=29 | Suspended | Sponsor: Binhui Biopharmaceutical Co., Ltd. | Trial completion date: Jan 2026 ➔ Dec 2026 | Recruiting ➔ Suspended | Trial primary completion date: Jun 2025 ➔ Dec 2026

Trial completion date • Trial primary completion date • Trial suspension • Breast Cancer • Melanoma • Solid Tumor

oHSV2-PD-L1/CD3-BsAb Administered Via Intramural Injection (clinicaltrials.gov) - P1 | N=29 | Recruiting | Sponsor: Binhui Biopharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting | Initiation date: Jun 2023 ➔ Dec 2023

Enrollment open • Metastases • Oncolytic virus • Trial initiation date • Breast Cancer • Melanoma • Oncology • Solid Tumor

oHSV2-PD-L1/CD3-BsAb Administered Via Intramural Injection (clinicaltrials.gov) - P1 | N=29 | Not yet recruiting | Sponsor: Binhui Biopharmaceutical Co., Ltd.

Metastases • New P1 trial • Oncolytic virus • Breast Cancer • Melanoma • Oncology • Solid Tumor

CC-OV01: First-in-human (FIH) Phase I Trial of BS-006 in Cervical Cancer (clinicaltrials.gov) - P1 | N=18 | Not yet recruiting | Sponsor: Zhongnan Hospital

New P1 trial • Cervical Cancer • Herpes Simplex • Oncology • Solid Tumor • Uterine Cancer